ReviewPharmaceutics2021
Osteoarthritis In Vitro Models: Applications and Implications in Development of Intra-Articular Drug Delivery Systems.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Experimental models of osteoarthritis: Advances, limitations and rational selection for translational research.Journal of orthopaedic translation · 2026Review
- Multivariate Analysis of Inflammatory and Regenerative Mediators in an In Vitro Canine Osteoarthritis System Treated with Platelet Gel Supernatants.Gels (Basel, Switzerland) · 2026Article
- M1 macrophage-derived migrasomes ameliorate temporomandibular joint osteoarthritis via autophagy.Journal of nanobiotechnology · 2026Article
- Sustained-Release Intra-Articular Drug Delivery: PLGA Systems in Clinical Context and Evolving Strategies.Pharmaceutics · 2025Review
- Forkhead box O proteins in chondrocyte aging and diseases.Journal of orthopaedic translation · 2025Review
- Beyond symptomatic alignment: evaluating the integration of causal mechanisms in matching animal models with human pathotypes in osteoarthritis research.Arthritis research & therapy · 2025Review
- Red Algae Alters Expression of Inflammatory Pathways in an OsteoarthritisPharmaceuticals (Basel, Switzerland) · 2025Article
- Microfluidic chip-based co-culture system for modeling human joint inflammation in osteoarthritis research.Frontiers in pharmacology · 2025Article
- Biomechanical and biological features of hyaluronic acid in combination with chondroitin and platelet rich plasma for regenerative medicine applications.Frontiers in bioengineering and biotechnology · 2025Article
- Animal Models of Osteoarthritis: Updated Models and Outcome Measures 2016-2023.Regenerative engineering and translational medicine · 2024Article
- Induction of Human Wharton's Jelly of Umbilical Cord Derived Mesenchymal Stem Cells to Be Chondrocytes and Transplantation in Guinea Pig Model with Spontaneous Osteoarthritis.International journal of molecular sciences · 2024Article
- Article
- In Vitro Models and Proteomics in Osteoarthritis Research.Advances in experimental medicine and biology · 2023Review
- Cartilage targeting therapy with reactive oxygen species-responsive nanocarrier for osteoarthritis.Journal of nanobiotechnology · 2022Article
- Article
- miRNA induced 3D bioprinted-heterotypic osteochondral interface.Biofabrication · 2022Article
- Modeling early changes associated with cartilage trauma using human-cell-laden hydrogel cartilage models.Stem cell research & therapy · 2022Article
- Thermo-Responsive Gel Containing Hydroxytyrosol-Chitosan Nanoparticles (Hyt@tgel) Counteracts the Increase of Osteoarthritis Biomarkers in Human Chondrocytes.Antioxidants (Basel, Switzerland) · 2022Article
- Exosomes in the Pathogenesis, Progression, and Treatment of Osteoarthritis.Bioengineering (Basel, Switzerland) · 2022Review
- A Progress Report and Roadmap for Microphysiological Systems and Organ-On-A-Chip Technologies to Be More Predictive Models in Human (Knee) Osteoarthritis.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a complex multi-target disease with an unmet medical need for the development of therapies that slow and potentially revert disease progression. Intra-articular (IA) delivery has seen a surge in osteoarthritis research in recent years. As local administration of molecules, this represents a way to circumvent systemic drug delivery struggles. When developing intra-articular formulations, the main goals are a sustained and controlled release of therapeutic drug doses, taking into account carrier choice, drug molecule, and articular joint tissue target. Therefore, the selection of models is critical when developing local administration formulation in terms of accurate outcome assessment, target and off-target effects and relevant translation to in vivo. The current review highlights the applications of OA in vitro models in the development of IA formulation by means of exploring their advantages and disadvantages. In vitro models are essential in studies of OA molecular pathways, understanding drug and target interactions, assessing cytotoxicity of carriers and drug molecules, and predicting in vivo behaviors. However, further understanding of molecular and tissue-specific intricacies of cellular models for 2D and 3D needs improvement to accurately portray in vivo conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.